Jonathan Kaplan, MD, MPH, Founder & CEO of DrWell, sat down with Modern Aesthetics at the 2026 Octane Aesthetics Tech Forum. As a panelist in the “GLPs and the Evolving Impact on Aesthetics” session, Dr. Kaplan explains what he believes will be disrupters to the industry this year, what is on the horizon for GLP-1 RAs, and the ideal patient for the once-daily oral semaglutide compared to the weekly injectable.
advertisement
Octane Aesthetics Tech Forum: GLP-1 RAs, ‘Fat You Can Take Off the Shelf’ to Be Major Changes in 2026
Share
Save
Restart
Resume
Transcript
Octane Aesthetics Tech Forum: GLP-1 RAs, ‘Fat You Can Take Off the Shelf’ to Be Major Changes in 2026
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Jonathan Kaplan, MD, MPH, Founder & CEO of DrWell, sat down with Modern Aesthetics at the 2026 Octane Aesthetics Tech Forum. As a panelist in the “GLPs and the Evolving Impact on Aesthetics” session, Dr. Kaplan explains what he believes will be disrupters to the industry this year, what is on the horizon for GLP-1 RAs, and the ideal patient for the once-daily oral semaglutide compared to the weekly injectable.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?